New immune-cell treatment for certain brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a type of immune-cell therapy (cytokine-induced killer cells) for people with certain grade 1–2 aggressive brain tumors that have already been treated with radiation and temozolomide. It aims to see whether the treatment can control the tumor and be tolerated safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give informed consent
- Your brain tumor is confirmed by biopsy as a grade 1–2 anaplastic glioma or glioblastoma
- You have already had standard radiation for a grade 3–4 astrocytic tumor with at least 40 Gy total dose
- You completed at least one full 28-day cycle of temozolomide taken daily for 5 days, and your tumor did not worsen and side effects were not too severe
- Your overall function is fair (Karnofsky score 60 or higher) and blood/organ tests are within limits
- You can use reliable birth control during the study (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immune cell treatment (called cytokine-induced killer cells) for advanced, grade 4 malignant glioma that has come back after prior therapy. It aims to slow or control the tumor by using your immune system after temozolomide treatment.
This trial tests a new approach using immune cells called cytokine-induced killer cells to treat glioblastoma. It aims to find the best way to prepare these cells to fight the tumor.
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
This early-stage study tests a treatment made from your tumor’s immune cells (TILs) to help shrink brain glioma. You may be considered if your glioma is back or has spread and standard options are no longer working (or don’t exist).
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
Hear when a new Cytokine-Induced Killer Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.